Congratulations to Lumox and the founders, Irati Beltrán Hernández and Sebas Pronk, on finalizing a license agreement with Utrecht Holdings for two foundational patents developed at Utrecht University. This agreement secures the exclusive rights to the core technology originating from Sabrina Oliveira’s research group, marking a critical step in transitioning this science from the lab to the clinic.
Securing intellectual property is a vital prerequisite for the investment required to fund large-scale drug production, safety studies, and clinical trials. This successful negotiation ensures that Lumox has the necessary framework to attract the capital needed to bring new therapies to patients, specifically targeting head and neck cancer.
This partnership serves as a model for effective tech transfer:
Market Readiness: Lumox gains the exclusivity needed to de-risk future investment.
Academic Impact: Utrecht University ensures its research reaches the public while maintaining a stake in its success.
Clinical Path: Breakthrough science moves closer to becoming a tangible treatment for patients.
A thank you to the team at Utrecht Holdings, including Danielle Counotte and Director Tessa Scharringhausen, for their collaborative approach to this deal. We look forward to seeing Lumox accelerate their development and move closer to their first clinical trials. 🥂